Clinicopathological variables | Entire cohort | Train cohort | Validation cohort | P-value |
---|---|---|---|---|
(N = 342) | (N = 230) | (N = 112) | ||
Status, N (%) | Â | Â | Â | 0.504 |
 Alive | 219 (64.0) | 144 (62.6) | 75 (67.0) |  |
 Dead | 123 (36.0) | 86 (37.4) | 37 (33.0) |  |
Age (years), N (%) | Â | Â | Â | 0.768 |
  ≤ 65 | 216 (63.2) | 147 (63.9) | 69 (61.6) |  |
 >65 | 126 (36.8) | 83 (36.1) | 43 (38.4) |  |
Gender, N (%) | Â | Â | Â | 0.961 |
 Female | 109 (31.9) | 74 (32.2) | 35 (31.2) |  |
 Male | 233 (68.1) | 156 (67.8) | 77 (68.8) |  |
T-stage, N (%) | Â | Â | Â | 0.412 |
 T1 | 168 (49.1) | 108 (47.0) | 60 (53.6) |  |
 T2 | 84 (24.6) | 55 (23.9) | 29 (25.9) |  |
 T3 | 74 (21.6) | 55 (23.9) | 19 (17.0) |  |
 T4 | 13 (3.8) | 9 (3.9) | 4 (3.6) |  |
 Unknow | 3 (0.9) | 3 (1.3) | 0 (0.0) |  |
N-stage, N (%) | Â | Â | Â | 0.411 |
 N0 | 239 (69.9) | 166 (72.2) | 73 (65.2) |  |
 N1 | 3 (0.9) | 2 (0.9) | 1 (0.9) |  |
 Unknow | 100 (29.2) | 62 (27.0) | 38 (33.9) |  |
M-stage, N (%) | Â | Â | Â | 0.453 |
 M0 | 244 (71.3) | 165 (71.7) | 79 (70.5) |  |
 M1 | 3 (0.9) | 1 (0.4) | 2 (1.8) |  |
 Unknow | 95 (27.8) | 64 (27.8) | 31 (27.7) |  |
AJCC stage, N (%) | Â | Â | Â | 0.213 |
 Stage I | 161 (47.1) | 105 (45.7) | 56 (50.0) |  |
 Stage II | 77 (22.5) | 51 (22.2) | 26 (23.2) |  |
 Stage III | 80 (23.4) | 61 (26.5) | 19 (17.0) |  |
 Stage IV | 3 (0.9) | 1 (0.4) | 2 (1.8) |  |
 Unknow | 21 (6.1) | 12 (5.2) | 9 (8.0) |  |
Grade, N (%) | Â | Â | Â | 0.56 |
 G1 | 53 (15.5) | 34 (14.8) | 19 (16.9) |  |
 G2 | 161 (47.1) | 104 (45.2) | 57 (50.9) |  |
 G3 | 111 (32.5) | 78 (33.9) | 33 (29.5) |  |
 G4 | 12 (3.5) | 10 (4.3) | 2 (1.8) |  |
 Unknow | 5 (1.5) | 4 (1.7) | 1 (0.9) |  |